IL13 and Alzheimer disease: Interestingly, biologics for AD that involve Th2 blockade via inhibition of IL-4 and/or IL-13 were associated with an increased incidence of ocular AEs, which led to the introduction of the new term: medication-induced ocular surface disease (mOSD) [41,102,103].